4cra: Difference between revisions
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design== | ==Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design== | ||
<StructureSection load='4cra' size='340' side='right' caption='[[4cra]], [[Resolution|resolution]] 1.80Å' scene=''> | <StructureSection load='4cra' size='340' side='right'caption='[[4cra]], [[Resolution|resolution]] 1.80Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4cra]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CRA OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[4cra]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4CRA OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4CRA FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=XJ8:N-[(1S)-2-[(2-AMINO-5-QUINOLYL)METHYLAMINO]-1-BENZYL-2-OXO-ETHYL]-4-HYDROXY-2-OXO-1H-QUINOLINE-6-CARBOXAMIDE'>XJ8</scene | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.8Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>, <scene name='pdbligand=XJ8:N-[(1S)-2-[(2-AMINO-5-QUINOLYL)METHYLAMINO]-1-BENZYL-2-OXO-ETHYL]-4-HYDROXY-2-OXO-1H-QUINOLINE-6-CARBOXAMIDE'>XJ8</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4cra FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4cra OCA], [https://pdbe.org/4cra PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4cra RCSB], [https://www.ebi.ac.uk/pdbsum/4cra PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4cra ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Disease == | == Disease == | ||
[ | [https://www.uniprot.org/uniprot/FA11_HUMAN FA11_HUMAN] Defects in F11 are the cause of factor XI deficiency (FA11D) [MIM:[https://omim.org/entry/612416 612416]; also known as plasma thromboplastin antecedent deficiency or Rosenthal syndrome. It is a hemorrhagic disease characterized by reduced levels and activity of factor XI resulting in moderate bleeding symptoms, usually occurring after trauma or surgery. Patients usually do not present spontaneous bleeding but women can present with menorrhagia. Hemorrhages are usually moderate.<ref>PMID:2813350</ref> <ref>PMID:1547342</ref> <ref>PMID:7888672</ref> <ref>PMID:7669672</ref> <ref>PMID:9401068</ref> <ref>PMID:9787168</ref> <ref>PMID:10027710</ref> <ref>PMID:10606881</ref> <ref>PMID:11895778</ref> <ref>PMID:15026311</ref> <ref>PMID:15180874</ref> <ref>PMID:15953011</ref> <ref>PMID:16607084</ref> <ref>PMID:18005151</ref> <ref>PMID:21668437</ref> <ref>PMID:21457405</ref> <ref>PMID:22016685</ref> <ref>PMID:22322133</ref> <ref>PMID:21999818</ref> <ref>PMID:22159456</ref> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/FA11_HUMAN FA11_HUMAN] Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 24: | Line 23: | ||
==See Also== | ==See Also== | ||
*[[Factor XIa|Factor XIa]] | *[[Factor XIa 3D structures|Factor XIa 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Akkaya | [[Category: Large Structures]] | ||
[[Category: Beisel | [[Category: Akkaya S]] | ||
[[Category: Eriksson | [[Category: Beisel HG]] | ||
[[Category: Erixon | [[Category: Eriksson PO]] | ||
[[Category: Fjellstrom | [[Category: Erixon K]] | ||
[[Category: Gustafsson | [[Category: Fjellstrom O]] | ||
[[Category: Jurva | [[Category: Gustafsson D]] | ||
[[Category: Kang | [[Category: Jurva U]] | ||
[[Category: Karis | [[Category: Kang D]] | ||
[[Category: Knecht | [[Category: Karis D]] | ||
[[Category: Nerme | [[Category: Knecht W]] | ||
[[Category: Nilsson | [[Category: Nerme V]] | ||
[[Category: Olsson | [[Category: Nilsson I]] | ||
[[Category: Oster | [[Category: Olsson T]] | ||
[[Category: Redzic | [[Category: Oster L]] | ||
[[Category: Roth | [[Category: Redzic A]] | ||
[[Category: Sandmark | [[Category: Roth R]] | ||
[[Category: Tigerstrom | [[Category: Sandmark J]] | ||
[[Category: Tigerstrom A]] | |||